Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 1,236 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 1,236 shares of the company’s stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $20.30, for a total transaction of $25,090.80. Following the sale, the insider now directly owns 77,099 shares in the company, valued at approximately $1,565,109.70. The trade was a 1.58 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Castle Biosciences Trading Down 0.8 %

Shares of CSTL traded down $0.16 during mid-day trading on Friday, reaching $19.94. 203,409 shares of the company’s stock traded hands, compared to its average volume of 369,865. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The stock’s 50-day moving average is $24.29 and its two-hundred day moving average is $28.07. Castle Biosciences, Inc. has a 12 month low of $16.97 and a 12 month high of $35.84. The stock has a market cap of $558.46 million, a P/E ratio of 99.70 and a beta of 0.98.

Hedge Funds Weigh In On Castle Biosciences

A number of large investors have recently bought and sold shares of CSTL. Covestor Ltd purchased a new stake in Castle Biosciences in the fourth quarter worth $25,000. R Squared Ltd purchased a new stake in shares of Castle Biosciences in the fourth quarter valued at approximately $42,000. Quest Partners LLC lifted its holdings in shares of Castle Biosciences by 54.4% in the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock worth $123,000 after buying an additional 1,522 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Castle Biosciences during the 4th quarter worth $128,000. Finally, Point72 DIFC Ltd bought a new position in shares of Castle Biosciences during the 3rd quarter worth $140,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on CSTL. Guggenheim set a $30.00 target price on shares of Castle Biosciences and gave the company a “buy” rating in a research report on Friday. Stephens reaffirmed an “overweight” rating and issued a $41.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 2nd. Finally, Robert W. Baird lifted their target price on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $38.75.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.